If confirmed, this hypothesis may provide a new perspective on the pathological diagnosis and therapy of ccRCC, especially concerning the synergistic combination of immunotherapy and glutaminase inhibitors. The gene discussed is GLS; the disease is nonpapillary renal cell carcinoma.